This study relying on structural similarities of protein–protein interfaces revealed that indinavir, tipranavir, and saquinavir originally used for HIV infection treatment may bind to EGFR-ERBB3 and/or EGFR-ERBB2 interfaces and can be repurposed for cancer treatment. Here, ERBB3 is linked to HIV infectious disease.